Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.50 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871865 | 0.98 | CA1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2109932 | 0.92 | STS (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL24861978 | 0.91 | AKT1 (0.53) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18662857 | 0.91 | AKT1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19331211 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19343523 | 0.83 | NPC1 (0.48) | CA1CA2CA12CA9CA14 | |
| SCHEMBL19343552 | 0.81 | ALDH1A1 (0.44) | CA1CA2CA12CA9CA14 | |
| Hydrochloric Acid SCHEMBL29425077 | 0.80 | LOXL2 (0.50) | CA1CA2CA12CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22615435 | 0.80 | LOXL2 (0.50) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL17508491 | 0.79 | LMNA (0.59) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | disclosed |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4532491-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| CN-103097358-A | Pharmaceutical composition | EISAI R&D MAN CO LTD | 2013-05-08 | — | — | CN | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| WO-2013004291-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012103071-A2 | COMPOUNDS AND COMPOSITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012039972-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-29 | — | — | WO | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| EP-2054401-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | Merck Frosst Canada Ltd. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | CA2 2566/4885GRIN2D 929/4885GRIN3B 443/4885 |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | CA2 3516/4885GRIN2D 2253/4885GRIN3B 1065/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | CA2 1914/4885GRIN2D 1660/4885GRIN3B 1036/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | CA2 1544/4885GRIN2D 2123/4885GRIN3B 1116/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | CA2 2262/4885GRIN2D 627/4885GRIN3B 597/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | CA2 1914/4885GRIN2D 1660/4885GRIN3B 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.